Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.78 -0.36 (-4.42%) Market Cap: 2.18 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 3.20 GF Score: 35/100

Iovance Biotherapeutics Inc at JMP Group Hematology and Oncology Summit (Virtual) Transcript

Dec 07, 2021 / 06:40PM GMT
Release Date Price: $18.78 (+10.93%)
Reni John Benjamin
JMP Securities LLC, Research Division - MD & Equity Research Analyst

And good afternoon, everyone. Welcome to the JMP Hematology & Oncology Summit. It's my pleasure to introduce the next presenting company, Iovance Biotherapeutics and here to talk about the company, Frederick Vogt, Interim CEO.

Questions & Answers

Reni John Benjamin
JMP Securities LLC, Research Division - MD & Equity Research Analyst

Just jumping right into it. We've talked about the full interim CEO title. I would love to just start off by asking what's happening there? How is the search going? And are there any updates you could provide?

Frederick G. Vogt
Iovance Biotherapeutics, Inc. - Interim President, CEO, General Counsel & Corporate Secretary

Sure. Yes. Right now, the search is going. We're -- the Board is committed to getting candidates in and talking with them and seeing if we can find the right person. I don't have any updates for you. This is one of those things where, at the very end, you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot